Doravirine RIF 357

Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of doravirine
Drug 1
Drug 1 dose
100 mg x 1
Drug 1 effect

AUC decreased 88%; Cmax decreased 57%, Cmin decreased 97%

Drug 2
Drug 2 dose
600 mg daily
Drug 2 effect

Not studied

Clinical Effects

Potential decrease in antiretroviral efficacy.

Management

Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.

Import ID
357